CD80 and neoplasm: As CTLA-4 has a stronger binding affinity for B7 ligands than does CD28, CTLA-4 competitively inhibits the ligation of B7 and CD28, thereby attenuating T cell proliferation and activation, and suppressing anti-tumor immunity [45,46,72].